Back

Choose your region

Relaunch of FamiCord Brand and Name Change of Vita 34 AG into FamiCord AG

We are pleased to announce the successful name change of Vita 34 AG to FamiCord AG.

This renaming reflects the integration of the Vita 34 Group and the PBKM FamiCord Group. The majority of our European subsidiaries already operate under the FamiCord brand. As the parent company, adopting the FamiCord name strengthens our unified identity and highlights our international recognition.

In Germany, our marketing efforts will continue under the Vita 34 consumer brand (www.vita34.de), while the corporate name FamiCord will be used in communications with investors, business partners, and employees across all regions.

This milestone also reflects the vision of Jakub. He co-founded PBKM in 2002, joined the company management in February 2005, and serves as a board member until today. Jakub’s belief in the purpose of the company and his ambition to become Europe’s leader in cell banking have guided us to this momentous achievement.

As FamiCord, we continue to build on our strong foundation:

  • A dedicated team of over 750 employees operating in 34 countries
  • Over 1,000,000 cord blood units and other biological materials stored to date
  • Contributions to treating more than 7,000 patients with stem cells sourced through us
  • 25+ years of industry leadership and innovation

We invite you to visit our website at www.famicord.com to familiarize yourself with our shared identity.

Together, we move forward as a proud and united FamiCord Family!

Recently added

  • FamiCord Group Recognized as Europe’s Leading Stem Cell Bank FamiCord is the largest stem cell bank in Europe and the third largest in the world. The quality of its services is validated by international certifications, and the company has now been recognized as Europe’s Leading Stem Cell Bank by Life Sciences Review, highlighting its commitment to excellence, clinical reliability, and innovation in stem cell banking.FamiCord Group have been awarded as “The Europe’s Leading Stem Cell Bank” , independent experts jury underlined FamiCord has established itself as a leading provider in the field, guiding families through the collection, processing, and long-term preservation of cord blood and perinatal tissues. Read more
  • Infantile cerebral palsy – Convincing evidence for the use of perinatal stem cells Leipzig, July 15, 2025 - Cerebral palsy (CP) continues to be one of the most common motor disabilities in childhood and is associated with permanent movement restrictions and spasticity. The therapeutic potential of stem cells from umbilical cord blood and tissue was discussed at the 37th Annual Meeting of the European Academy Of Childhood-onset Disabilities (EACD) and the 4th Meeting of the International Alliance of Academies of C hildhood Disability (IAACD) from June 24 - 28, 2025 in Heidelberg. As part of a symposium supported by FamiCord AG, international experts presented the current state of research and reported on the results from clinical practice. Read more